Table 6.

Treatment-emergent adverse events for all causalities (multiple dose)

Number of subjects (%) with adverse events [number of adverse events]
System organ class	Placebo		Dose of selisistat
	Male (n = 6)	Female (n = 6)	Male 100 mg once daily (n = 6)	Male 300 mg once daily (n = 6)	Male 100 mg twice daily (n = 6)	Female 100 mg twice daily (n = 6)
Gastrointestinal disorders
Diarrhoea		1 (50%) [1]		1 (17%) [1]		1 (17%) [1]
Abdominal pain upper		1 (50%) [1]				1 (17%) [1]
Constipation		1 (50%) [1]				1 (17%) [1]
Nausea		1 (50%) [1]				1 (17%) [1]
Flatulence						1 (17%) [1]
Abdominal distension			1 (17%) [1]
Total		2 (100%) [4]	1 (17%) [1]	1 (17%) [1]		3 (50%) [5]
Nervous system disorders
Headache	1 (17%) [2]			1 (17%) [1]
Dizziness						1 (17%) [1]
Total	1 (17%) [2]			1 (17%) [1]		1 (17%) [1]
Musculoskeletal and connective tissue disorders
Neck pain					1 (17%) [1]
Back pain	1 (17%) [1]	1 (17%) [1]
Total	1 (17%) [1]	1 (17%) [1]			1 (17%) [1]
Skin and subcutaneous tissue disorders
Rash	1 (17%) [1]	1 (17%) [1]		1 (17%) [1]
Total	1 (17%) [1]	1 (17%) [1]		1 (17%) [1]
Ear and labyrinth disorders
Hearing impaired						1 (17%) [1]
Total						1 (17%) [1]
Infections and infestations
Nasopharyngitis	1 (17%) [1]		1 (17%) [1]
Total	1 (17%) [1]		1 (17%) [1]
Injury, poisoning and procedural complications
Arthropod bite				1 (17%) [1]
Total				1 (17%) [1]
Metabolism and nutrition disorders
Decreased appetite	1 (17%) [1]
Total	1 (17%) [1]
Renal and urinary disorders
Micturition urgency					1 (17%) [1]
Total					1 (17%) [1]
Respiratory, thoracic and mediastinal disorders
Epistaxis					1 (17%) [1]
Total					1 (17%) [1]
General disorders and administration site conditions
Fatigue					1 (17%) [1]
Total					1 (17%) [1]
Overall total	3 (50%) [6]	2 (100%) [6]	2 (33%) [2]	2 (33%) [4]	3 (50%) [3]	6 (100%) [8]

n = number of subjects studied.